1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028

Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028

  • July 2019
  • 83 pages
  • ID: 5824454
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028

Summary
Hidradenitis Suppurativa (HS) is a chronic, inflammatory, debilitating skin disease that is characterized by the recurrent development of painful nodules and abscesses that rupture.This leads to the formation of sinus tracts and scarring on the skin.

The exact cause of HS is unknown, and it is hypothesized that genetic and environmental factors are the key causes of the disease Environmental factors such as smoking, obesity, and being overweight are considered to be trigger factors in HS development.Additionally, genetic factors are also believed to play a key role in the development of HS.

DNA studies have revealed that approximately one-third of patients with HS have a family history of HS. Studies have also shown that there are inheritance patterns within families who are affected by HS.

The analyst estimates the 2018 sales for the HS market at approximately $898 million across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK) and Japan. Over the course of the 10-year forecast period, the HS market will grow at a Compound Annual Growth Rate (CAGR) of 7.2% across the 7MM. Each of the 7MM are anticipated to grow significantly, recording CAGRs of 9.9%, 1.2% and -0.5% across the US, 5EU and Japan, respectively. At the end of 2028, the US will account for 79.1% of sales across the 7MM, while the 5EU and Japan will account for around 20.9% of sales. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of HS in the region, as well as the anticipated high annual cost of therapy (ACOT) of biologics in the US market.

Key Questions Answered
- How will the HS market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2018-2028?
- What are the most promising late-stage pipeline drugs in HS?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the greatest unmet needs in HS? Will the pipeline drugs fulfil these needs of the market?
- What are the largest opportunities in the HS landscape?

Scope
- Overview of HS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline HS market revenue from 2018-2028. ACOT and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HS therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global HS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HS therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides an overview of the Ischemia ...

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019SummaryInterleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded ...

Integrin Beta 1 - Pipeline Review, H2 2019

Integrin Beta 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Integrin Beta 1 - Pipeline Review, H2 2019SummaryIntegrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Integrin beta-1 also known as CD29 is a ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on